It is recognised that breast tumours with an oestrogen receptor level > 10 fmol per mg of protein have a greater chance of responding to endocrine therapy such as tamoxifen (Allegra et al., 1980; Rubens & Hayward, 1980; Young et al., 1980; Fisher et al., 1983) . Studies have also demonstrated that the higher the oestrogen receptor level the greater the chance of response (Hayward et al., 1977; Paridaens et al., 1980; Campbell et al., 1981; Osborne et al., 1980; Fisher et al., 1983) . The oestrogen receptor level does not, however, correlate with the duration of response to treatment and therefore gives no indication of relapse in an individual tumour (Allegra et al., 1980) .
There has been no previously reported biological predictor of relapse to tamoxifen therapy. Serum tumour markers (such as CA15-3) have only limited use and, apart from the observation of progressive clinical disease, there is no method of investigation that can determine whether a primary tumour is responding to primary medical treatment, including tamoxifen. As this is a late event in the natural history of the disease, it could be of benefit to predict relapse before it becomes clinically evident. This is of particular importance as the role of primary tamoxifen alone in the treatment of early breast cancer is now highly controversial. A recent update from the CRC tamoxifen study for patients > 70 years of age suggested a possible worse survival for patients treated by tamoxifen alone in comparison with patients treated by immediate surgery (Bates et al., 1992) . It is theoretically possible that earlier detection of relapse before it became clinically evident could reduce any survival disadvantage caused by ineffective primary tamoxifen therapy.
Tamoxifen has been shown to have significant effects on the proliferation characteristics of breast cancer cell lines grown in culture (Sutherland et al., 1983; Osborne et al., 1984; Lykkesfeldt et al., 1986) . While some investigations in vivo have failed to confirm these findings (Baildam et al., 1987; Brunner et al., 1989 ), Clarke et al. (1993 have observed a reduction in expression of the proliferationrelated marker, Ki67, in human breast tumours during treatment with tamoxifen. Although tamoxifen can take many months to achieve its full clinical effect, none of the previously reported studies have analysed the long-tern effects of tamoxifen on S-phase fraction (SPF) or DNA index (DI) of the tumour.
The aim of this pilot study was first to determine the reliability and reproducibility of repeat sequential fine-needle aspirates (FNAs) in determining the DNA content from breast tumours in vivo and, then, using this technique, to determine whether flow cytometry of FNAs could be used to monitor and predict the likely response of these primary breast tumours to tamoxifen.
We report the results on 21 patients undergoing treatment with primary tamoxifen. The data suggest that changes in the DI and SPF may be useful parameters in the management of these patients.
Materials and methods

Patients
From January 1991 to June 1992, 27 patients with primary breast tumours were treated with tamoxifen alone either as part of the CRC trial of primary tamoxifen versus immediate surgery in patients over 70 years (Bates et al., 1992) In the other six cases (patients 4-9) there was a reduction in SPF alone (with no change in ploidy) of greater than 50% of the pretreatment level with a >3% difference in the absolute values (see Figure 4 ). This degree of difference was not seen in any cases of repeat sampling with no intervening therapy and could not simply be explained by intratumoral heterogeneity alone. The reduction in SPF was seen on average 4.5 months (Table II , patients 4-9) before clinical CR was achieved, although the patients had been on tamoxifen on average for only 2 months.
Patients failing to show complete response (PR or PD) In four cases (patients 11-14) , in which the tumours were diploid in the pretreatment sample, a change to aneuploid (see Figure 4 ) was detected in a FNA taken on average 6 months after starting tamoxifen treatment. In two cases (patients 12 and 13), a preceding sample taken while the patient had been on tamoxifen for at least 3 months had also been recorded as diploid. In three of these cases (patients 1 1-13) the tumours achieved a partial response to tamoxifen and the changes in ploidy were detected even while the patient was still in partial remission. However, all four patients subsequently showed clinical signs of tumour progression which occurred with a mean lead time of 5 months after detecting the change in ploidy. In two cases (patient 11 and 13) this clinical progression was still <25% and was therefore scored into a NC category. In six cases (patients 15-20) repeat sequential aspirates showed no change in ploidy with either no change or a rise in SPF of > 50% with a > 3% difference in the absolute value. In four of these cases there was no clinical response to tamoxifen and all showed tumour progression of > 25% with a mean lag time of 7 months between the recorded post-tamoxifen sample and clinical progression. In two cases (patients 17 and 18 in Table II (Prey et al., 1985; Erhardt & Auer, 1986; Remvikos et al., 1991) which have all shown good correlation between sequential FNAs from the same tumour. Only one study (Mullen & Miller, 1989) has commented on significant variation in DNA analysis caused by intratumoral heterogeneity between two fine-needle aspirates taken from the same tumour. Even here a com-parison of DI between two needle aspirates showed less than 5% variation in 10 out of 11 cases.
Greater variation has been obtained when comparing FNAs with paraffin section from the same tumour (Greenbaum et al., 1984; Prey et al., 1985; Kalloniemi, 1988) . This may explain why some studies in which both techniques have been employed have failed to obtain any consistent changes in DNA content in breast tumours after tamoxifen therapy (Baildam et al., 1987) . These reported differences may also relate to other factors such as tumour size. It is more difficult to sample uniformly across a large tumour which is also more likely to be heterogeneous in terms of the proliferation characteristics of its individual cells. It should therefore be noted that in this study 18/21 of cases had tumours <5 cm in diameter. Also, considerable care was taken to sample widely from several areas within the same tumour. This is not possible when a paraffin-embedded tissue section is taken from the tumour after surgery if only one 40-nLm section of tumour is taken for analysis.
The results of this study have shown that, providing any sample with a CV > 10% on flow cytometry or diploid with <100 malignant cells per cytospin slide was removed from the analysis, significant intratumoral heterogeneity was seen in only one case (patient 10).
In this pilot study, we were able to monitor changes in only 21 out of 27 patients. However, this was part of a multifactorial study. Material for 12 cytospins was taken from the aspirate before storing the remainder of the sample for flow cytometry. We would expect a higher success rate from aspirates taken for one cytospin (conventional cytological stain) and flow cytometry only. If these measurements are shown to be of real benefit in patient management, patient recall to obtain a repeat sample would be justified.
The use of an FNA to monitor treatment Considering the data from the FNAs taken sequentially during treatment, the clearest indication of successful therapy was a failure to observe malignant cells by conventional cytology in the post-treatment sample. This was also reflected in the flow cytometry in that only diploid cells were detected in the post-treatment samples of what had previously been recorded as aneuploid tumours (patients 1-3). However, in six patients, a reduction in the SPF was recorded by flow cytometry before the disappearance of malignant cells from the aspirate (patients 4-9).
In seven patients, tumours were shown to be aneuploid and sequential FNAs showed either no change or a rise in SPF. These cases showed eventual tumour progression with an increase in tumour size which in only one patient was still insufficient (<25%) to classify as PD. There was a median lead time of 7 months between the repeat FNA result and eventual tumour progression (see Table II , patients 15-21).
The difference in SPF between pre-and post-treatment samples for tumours achieving a complete response versus those only reaching a partial response or less was significantly different (P<O.O1) even with the small numbers in the study.
In four patients (patients 11-14) a change from diploid to aneuploid was observed while the tumours were still in partial remission and on average after only 6 months of therapy. All these cases eventually showed clinical evidence of tumour progression. However, the change in ploidy was picked up with a mean lead time of 5 months before progression was detected clinically. This change was presumably caused by regression of the main diploid component and subsequent growth of a small aneuploid component already present within the tumour or from clonal development of a new cell population (Nowell, 1976) . This is consistent with data (Kute et al., 1985) showing that diploid tumours are more likely to be oestrogen receptor positive and hence respond to tamoxifen.
A change from diploid to aneuploid or a rise in SPF may reveal a failure in therapy even before changes in tumour size become evident. Conversely, a rapid decrease in the number of malignant cells in an FNA which was initially cellular or a fall in SPF may indicate a complete response. These data suggest that monitoring the changes in DI and SPF in patients on tamoxifen may enable the physician to select which patients are most likely to obtain a complete response or not to primary tamoxifen therapy. A larger study to investigate these changes further is therefore warranted.
